Measles and rubella elimination country profile Montenegro



Measles elimination status

2016 eliminated 2017 eliminated

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvo

Measles and rubella surveillance

National case-based surveillance for Lab confirmation for diagnosis of

Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

Measles and rubella immunization schedule. 2017

	Vaccine	Schedule	Year of introduction	
MCV1	MMR	13 months	MCV2	1994
MCV2	MMR	6 years	RCV	1994
N	Yes			

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring_surveillance/data/en/)
MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine;

MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccin


Definition used for an outbreak

There is no "classic" definition of a measles outbreak in Montenegro as country is in the elimination phase. Defining and outbreak is based on several parameters with the main one being number of endogenous cases, burden of the healthcare services and other



Source: Measles and rubella elimination Annual Status Update report, 2017

Confirmed measles cases by month of onset, 2013-2017



Source: CISID 2017

Rubella elimination status

2016 eliminated 2017 eliminated


Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvo

Demographic information, 2017

Total population	628 960
< 1 year old	6880
< 5 years old	35 780

Source: World Population Prospects: The 2017 Revision, New York, United Nations

Measles and rubella cases and immunization coverage, 2008-2017



Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics,

Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring_surveillance/data/en/)

MCV1 = first dose of measles-containing vaccine

MCV2= second dose of measles-containing vaccine



Measles and rubella elimination country profile Montenegro



Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected measles		Confirmed m	neasles cases	Discarded as	Measles	Genotypes	
	cases	Laboratory	Epi- linked	Clinically	Total	non- measles	incidence	detected
2013	10	0	0	0	0	10	0	NA
2014	65	7	0	ND	7	60	6.5	ND
2015	19	13	2	0	15	4	16	ND
2016	3	0	0	0	0	3	0	NA
2017	6	0	0	0	0	6	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017

Incidence calculated per 1 million population ND = Data not available; NA= Not applicable

Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected rubella		Confirmed r	ubella cases	Discarded as	Rubella	Genotypes	
	cases	Laboratory	Epi- linked	Clinically	Total	non- rubella	incidence	detected
2013	7	0	0	0	0	7	0	NA
2014	7	0	0	0	0	7	0	NA
2015	8	0	0	0	0	8	0	NA
2016	0	0	0	0	0	0	0	NA
2017	6	0	0	0	0	6	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017 Incidence calculated per 1 million population

ND = Data not available; NA= Not applicable

Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non- measles rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	1.6	33.3%	100%	NA	ND	ND	NA	ND
2014	0.8	19%	91.6%	100%	7	0%	0	ND
2015	9.5	9.5%	100%	100%	19	79%	0	0%
2016	4.8	30.4%	100%	NA	30	0%	NA	0%
2017	0	14.3%	100%	NA	0	NA	NA	0%

Source: ASU 2013-2017

ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella surveillance and laboratory performance indicators, 2013-2017

	Discarded non- rubella rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigtion	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	1.1	33.3%	100%	NA	ND	ND	NA	ND
2014	1.1	19%	100%	NA	0	0%	0	ND
2015	1.3	14.3%	100%	NA	8	0%	0	0%
2016	12.9	73.9%	100%	NA	72	0%	NA	0%
2017	0	19%	100%	NA	0	NA	NA	0%

Source: ASU 2013-2017

ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Montenegro in 2017 and confirmed that measles and rubella elimination has been sustained. The RVC commends the recent nomination and accreditation of a National Measles and Rubella Reference Laboratory in Montenegro. However, the RVC is extremely concerned over the continuing low vaccination coverage, resulting in a dangerous accumulation of susceptible children across the country and creating a high risk for re-establishing endemic transmission. The RVC urges efforts to increase vaccination coverage and close existing immunity gaps.

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc

Surveillance performance indicators and targets

- a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- b. % cases with adequate laboratory investigation: ≥ 80%
- c. % origin of infection known: \geq 80%
- d. Rate of viral detection: ≥ 80%

Supplementary immunization activities

Year	Target age	Vaccine used	% Coverage
2017	1-6Y	MMR	88%
2016	0-12Y	MMR	30.3%
2016	0-12Y	MMR	68.4%

Source: Supplementary immunization activities, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MMR = measles-mumps-rubella vaccine ND = Data not available

Information on CRS, 2017

No cases reported



Source: Measles and rubella elimination Annual Status Update report, 2017 CRS = congenital rubella syndrome